LiveNSE delayed · 128/128 · 20 Aug 2026, 11:34 am
Scores stay the 15 Aug 2026 desk snapshot. Not advice.
CONCORDBIO · Healthcare · Small Cap · Live 20 Aug 2026, 11:34 am · Discovery

Concord Biotech Ltd

Fermentation-API specialist with high margins and a recently listed book. Quality is high; the starting multiple is not modest.

10X Low
Moderate Risk
Attractive Entry
Compounder
Institutional Accumulation
Multibagger score
61.1/100
Market cap
₹16,551 Cr
Last price · live
₹1,582.4
−5.10 (−0.32%)
52W
₹987–₹1,802

Implied P/E 45.4x · CONCORDBIO.NS · delayed NSE

10X potential (scenario)
LOW
Base multiple
1.8x
Bull multiple
3.8x
Classification
Potential Mid Cap

Base case compounds into a durable mid-cap, not yet large-cap scale.

Final investment scorecard

Multibagger61.1 / 100
10X potentiallow
Business quality7.0 / 10
Growth runway6.8 / 10
Competitive advantage7.6 / 10
Management6.8 / 10
Balance sheet7.8 / 10
Valuation2.7 / 10
Technical setup8.2 / 10
Riskmoderate

Why it could become a multibagger

  • Scarce fermentation capacity with software-like margins and a real factory.
  • Cash and earnings agree with each other.

What needs to go right

  • New molecules commercialise
  • Yields hold at new plants
  • No FDA surprise

What could destroy the thesis

  • A regulatory action
  • A customer insourcing
  • Price erosion in a key API

What would make me sell

  • An FDA warning letter
  • Gross margin <50% for two halves
  • A large unrelated acquisition

Key metrics to monitor

Gross margin
ROCE
FCF
New-molecule sales
USFDA status
Customer mix

Illustrative FY25 / TTM desk snapshot compiled for this terminal. Not a live NSE/BSE feed. Cross-check annual reports, exchange filings and investor presentations before use.